These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1710750)

  • 1. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
    Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
    Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ
    Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
    Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
    Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Roehrborn CG
    Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Van Kerrebroeck P; Nordling J
    BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
    Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.